These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 25710563)

  • 1. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Solis-Herrera C; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1402-1407. PubMed ID: 29342295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
    Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.
    Abdul-Ghani M; Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA
    Diabetes; 2017 Sep; 66(9):2495-2502. PubMed ID: 28611037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control.
    Jeon HJ; Ku EJ; Oh TK
    Diabetes Res Clin Pract; 2018 Aug; 142():188-194. PubMed ID: 29807104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
    J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
    Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
    Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin: more than just another oral glucose-lowering agent?
    Katsiki N; Papanas N; Mikhailidis DP
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.